Skip to main content
Journal cover image

Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review

Publication ,  Journal Article
Lyman, GH; Abella, E; Pettengell, R
Published in: Critical Reviews in Oncology/Hematology
2014

Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of myelosuppressive chemotherapy that usually results in hospitalization and the need for intravenous antibiotics. FN may result in dose reductions, delays, or even discontinuation of chemotherapy, which, in turn, may compromise patient outcomes. It is important to identify which patients are at high risk for developing FN so that patients can receive optimal chemotherapy while their risk for FN is appropriately managed. A systematic review of the literature was performed to gain a comprehensive and updated understanding of FN risk factors. Older age, poor performance status, advanced disease, certain comorbidities, low baseline blood cell counts, low body surface area/body mass index, treatment with myelosuppressive chemotherapies, and specific genetic polymorphisms correlated with the risk of developing FN. Albeit many studies have analyzed FN risk factors, there are several limitations, including the retrospective nature and small sample sizes of most studies. © 2013 Elsevier Ireland Ltd.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Critical Reviews in Oncology/Hematology

DOI

ISSN

1040-8428

Publication Date

2014

Volume

90

Issue

3

Start / End Page

190 / 199

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., Abella, E., & Pettengell, R. (2014). Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Critical Reviews in Oncology/Hematology, 90(3), 190–199. https://doi.org/10.1016/j.critrevonc.2013.12.006
Lyman, G. H., E. Abella, and R. Pettengell. “Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.” Critical Reviews in Oncology/Hematology 90, no. 3 (2014): 190–99. https://doi.org/10.1016/j.critrevonc.2013.12.006.
Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Critical Reviews in Oncology/Hematology. 2014;90(3):190–9.
Lyman, G. H., et al. “Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.” Critical Reviews in Oncology/Hematology, vol. 90, no. 3, 2014, pp. 190–99. Scival, doi:10.1016/j.critrevonc.2013.12.006.
Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Critical Reviews in Oncology/Hematology. 2014;90(3):190–199.
Journal cover image

Published In

Critical Reviews in Oncology/Hematology

DOI

ISSN

1040-8428

Publication Date

2014

Volume

90

Issue

3

Start / End Page

190 / 199

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1102 Cardiorespiratory Medicine and Haematology